(Circulation. 1995;92:2163-2168.)
© 1995 American Heart Association, Inc.
Articles |
Osteopontin Is Expressed in Human Aortic Valvular Lesions
Presented in part at the 66th Scientific Sessions of the American Heart Association, Atlanta, Ga, November 8-11, 1993.
From the Division of Cardiology, Department of Medicine (K.D.O., J.K., C.M.O.), and Department of Pathology (D.D.R., M.F., C.G., C.E.A.), University of Washington, Seattle.
 |
Abstract |
|---|
 Top Abstract IntroductionMethods Results Discussion References |
|---|
Background Nonrheumatic stenosis of trileaflet aortic valves, in which calcification is a prominent feature, has been termed a "degenerative" condition, but it has been demonstrated recently that chronic inflammation is a characteristic feature of the developing lesion of aortic stenosis. This observation raised the possibility that calcification in the aortic valve might be actively regulated. Thus, the present study investigated whether osteopontin, a protein implicated in the regulation of both normal and dystrophic calcification, could be detected in lesions of valvular aortic stenosis.
Methods and Results Morphological and immunohistochemical studies were performed on 14 human aortic valves, representing a range of pathology from normal to clinically stenotic. The extent of calcification and macrophage accumulation and their relation to the presence of osteopontin protein were characterized. Highly statistically significant associations were found between the degree of osteopontin expression and the degrees of both calcification and macrophage accumulation in early through late lesions of aortic stenosis. Further, in situ hybridization localized osteopontin mRNA to a subset of lesion macrophages.
Conclusions These results suggest that, rather than representing a degenerative and unmodifiable process, calcification in aortic stenosis may be, in part, an actively regulated process with the potential for control either through modification of inflammation or synthesis of proteins such as osteopontin, which may modulate calcification in this tissue.
Key Words: osteopontin • aorta • valves • stenosis • calcium
|
Introduction |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
Nonrheumatic aortic valvular stenosis is a common disease of the elderly, in whom the estimated prevalence of critical aortic stenosis is 2.9%.1 Stenosis of a trileaflet aortic valve has been termed a "degenerative" condition,2 3 4 5 but recent studies have demonstrated that the developing lesion of aortic stenosis has many components of a chronic inflammatory process, including accumulation of both macrophages and lymphocytes.6 Further, calcification is prominent in valvular aortic stenosis and has important functional consequences.2 3 4 5 Recognition of an association of inflammatory cell accumulation with developing aortic valve lesions led us to investigate the possibility that protein mediators of calcification might be present in aortic valve leaflets.
One protein thought to play a role in calcification is osteopontin. Osteopontin is a highly acidic, 44-kD glycoprotein7 8 9 and is one of a group of noncollagenous matrix proteins of bone.9 10 11 12 13 It also has been implicated in cell adhesion and spreading14 and in cell cycling.15 Osteopontin binds readily to hydroxyapatite10 and may mediate adherence of osteoblasts and osteoclasts to bone matrix through an arginine-glycine-aspartate (RGD) integrin-binding sequence.7 Osteopontin also has been implicated in dystrophic calcification; specifically, the protein is present in renal stones,16 and its secretion by renal distal tubules is upregulated in a rat model of nephrolithiasis.17 However, there is controversy as to whether osteopontin promotes16 17 or inhibits18 renal stone formation. Further, several studies recently have demonstrated associations of osteopontin with both calcification and atherosclerosis in human arteries.19 20 21 22 23 In contrast, arterial levels of osteonectin, another noncollagenous bone matrix protein, have been shown to decrease as atherosclerosis and calcification developed.19
Therefore, demonstration of an association between the presence of osteopontin and calcification in human aortic valves would be consistent with the hypothesis that calcification in this tissue is, at least in part, actively mediated rather than a merely passive, or degenerative,2 3 4 5 phenomenon. The present study was undertaken to address the following specific questions: (1) Is osteopontin preferentially present in diseased compared with normal aortic valves? (2) If so, is osteopontin associated with calcification or inflammatory cell accumulation? and (3) Which cells produce this protein?
|
Methods |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
Human Aortic Valvular Tissue
Human aortic valvular tissue used for morphological and histochemical analysis was 11 valves obtained at autopsy from patients without clinical aortic stenosis and 3 valves obtained at surgery from patients undergoing valve replacement for clinical aortic stenosis. The valve leaflets were fixed in methanol Carnoy's fixative (60% methanol, 30% chloroform, 10% acetic acid) and embedded in paraffin. Sections of the leaflets were stained with hematoxylin-eosin or with Verhoeff–van Gieson's stain for valve morphology and with von Kossa's stain to identify calcium phosphate mineral.
For in situ hybridization studies, an additional 9 leaflets were obtained from the native hearts of patients undergoing cardiac transplantation for ischemic or idiopathic cardiomyopathy and were fixed in formalin within 2 hours of organ removal to minimize ex vivo mRNA degradation. Although none of these patients had either clinically evident or echocardiographically detectable aortic stenosis, some of the leaflets contained early or moderate aortic valvular lesions.6
Immunohistochemical Reagents: Antibodies and
Antisera
Immunohistochemistry was performed with the following
antibodies: (1) LF7, a rabbit polyclonal anti-osteopontin antiserum
raised against human bone–derived osteopontin12 and
used previously for immunohistochemistry on human arterial
tissue,20 23 was a kind gift of Dr Larry Fisher and
was
used at a titer of 1:1000 to localize osteopontin
protein20 ; (2) mouse monoclonal antibody
anti-CD68,24 used at a titer of 1:1000 to identify
macrophages; and (3) mouse monoclonal antibody anti–smooth
muscle 
-actin,25 used at a titer of 1:1000 to
identify cells with contractile proteins, which in the context of
aortic valvular tissue might represent either
myofibroblasts or smooth muscle cells (SMCs).
Immunohistochemistry
Single-label immunoperoxidase staining
of 6-µm
aortic valve sections was performed as described
previously.26 27 Briefly, tissue sections were
deparaffinized with xylene and then rehydrated with graded alcohols.
The slides were blocked with 3% H2O2,
washed with PBS, incubated for 30 minutes with the primary antiserum or
antibody, and then washed again with PBS. A biotin-labeled
secondary antibody, either anti-rabbit (for LF7) or anti-mouse
(for anti–smooth muscle -actin or anti-CD68), then was
applied for 30 minutes, followed by an avidin-biotin-peroxidase
conjugate (ABC Elite; Vector Laboratories) for 30 minutes.
3,3'-Diaminobenzidine with nickel chloride was used as a chromogen,
yielding a black reaction product. Cell nuclei were counterstained
with methyl green. On formalin-fixed tissue, nickel chloride was
omitted from the 3,3'-diaminobenzidine chromogen reaction, thus
yielding a brown reaction product, and sections were counterstained
with hematoxylin.
Negative controls included substitution of primary antiserum/antibody with PBS or with either nonimmune rabbit serum or irrelevant antibodies, as appropriate, at the same titer.
Statistical Analysis
The statistical validity of the apparent
associations between
osteopontin and calcification and between osteopontin and
macrophage accumulation was evaluated in the following fashion.
The leaflet from each of the 14 patients was divided into three
segments: the base, the midportion, and the tip; each segment was then
evaluated for osteopontin, macrophage accumulation, and
calcification. Each of these characteristics was graded on a
semiquantitative scale, ranging from 0, which represented
none or normal, up to 4, which represented the most
widespread distribution of the characteristic. Associations between
osteopontin and calcification and between osteopontin and
macrophage accumulation then were examined with
Mantel-Haenszel's test for linear association with
SPSS/PC+ statistical software. Significance was set at
the P<.05 level.
Riboprobe Preparation
A 1.5-kb human osteopontin cDNA (clone
OP10) cloned into the
vector pBluescript SK (fl-) (Stratagene) was a kind gift of Dr Larry
Fisher, National Institutes of Health. The plasmid was linearized with
Xba I for antisense riboprobe transcription or with
Xho I for sense (control) riboprobe transcription. Reagents
for riboprobe synthesis were obtained from Promega, except for
35S-UTP (1000 to 3000 Ci/mmol), which was obtained from New
England Nuclear.
The riboprobe transcription reaction mixtures contained 1 µg cDNA; 250 µCi 35S-UTP; 500 µmol/L each of rATP, rCTP, and rGTP; 40 U RNasin (Promega); 10 mmol/L DTT; 40 mmol/L Tris; and 10 U of either T7 polymerase (for antisense transcription) or T3 polymerase (for sense transcription). After 60 to 75 minutes of incubation at 37°C, the cDNA was digested by addition of 1 U RQ1 DNase (Promega), and incubation was continued for an additional 15 minutes at 37°C. Free nucleotides were separated in a Sephadex G-50 column, and the riboprobes were used within 24 hours of synthesis.
In Situ Hybridization
Formalin-fixed, paraffin-embedded
6-µm-thick aortic valve sections were deparaffinized according to
standard protocols.26 27 The sections were washed
with
0.5x standard saline citrate (SSC) (1xSSC=150 mol/L NaCl,
15 mol/L
sodium citrate, pH 7.0) and digested with proteinase K (1 mg/mL) (Sigma
Chemical Co) in RNase A (Promega) buffer. After several 0.5xSSC
washes, 50 µL prehybridization buffer (0.3 mol/L NaCl, 20 mmol/L
Tris, pH 8.0, 5 mmol/L EDTA, 1x Denhardt's solution, 1x
dextran
sulfate, 10 mmol/L DTT) was applied for 2 hours. For hybridizations,
35S-labeled antisense riboprobe (300 000 cpm in 50 µL
prehybridization buffer) was added, and hybridizations were allowed to
proceed overnight at 50°C. After hybridization, sections were washed
with 0.5xSSC, treated with RNase A (20 µg/mL) for 30 minutes, and
washed twice in 2xSSC, followed by three high-stringency washes in
0.1xSSC/Tween 20 (Sigma) at 37°C, followed by several 2xSSC
washes.
After air-drying, the tissue was dipped in NTB2 nuclear emulsion
(Kodak) and exposed in the dark for 10 days. After development, the
sections were counterstained with hematoxylin-eosin.
|
Results |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
Immunohistochemistry
Association of Osteopontin With Calcification and Macrophage Accumulation
On the 14 valve leaflets fixed in methanol Carnoy's solution, two general patterns of calcification could be seen. The most common pattern of osteopontin protein expression was an association of osteopontin with both calcification and macrophage accumulation, as demonstrated in Fig 1
. These
photomicrographs were obtained at the junction of the midportion of the
leaflet and the leaflet tip. The aortic surface of the leaflet is
located at the top of the sections. This developing aortic
valvular lesion is characterized by displacement and
fragmentation of the basement membrane and accumulation of lipid,
protein, and cells. Comparison of Figs 1A and 1B
demonstrates that in
the lower left portion of each section, black areas of calcium mineral
deposition (Fig 1A) are surrounded by osteopontin protein (Fig
1B). In
this region of the lesion, macrophages also could be found (Fig
1C). Fig 1B demonstrates that much of the
osteopontin protein appears
to be extracellular. However, occasional cells in closest proximity to
the bulk of the osteopontin staining have intracellular staining for
the osteopontin protein and, by comparison with Fig 1C, appear
to be
macrophages. In contrast, other subsets of macrophages
located near the surface of the leaflet and below the region of
calcification at the junction between the fibrosa and
ventricularis are negative for the osteopontin protein.
These findings raise the possibility that a subset of lesion
macrophages is actively producing and secreting osteopontin to
modulate extracellular calcification in this area. Staining with the
antibody against -actin was negative in this region (data not
shown). This pattern of osteopontin expression in association with
calcification and macrophage accumulation was present in
leaflets from 9 of 14 patients.
|
Association of Osteopontin
With Calcification
The second pattern of osteopontin expression, shown
in Fig 2, was of focal areas of calcification seen in
association with osteopontin deposition in areas without inflammatory
cell infiltrate. The Verhoeff–van Gieson (Fig 2A) and
hematoxylin-eosin (Fig 2B) stains demonstrate a region of a
valve
leaflet with mild thickening of the fibrosa (upper layer of the valve
leaflet). The aortic surface of the valve is at the top of the leaflet,
with the ventricular surface at the bottom. The leaflet
consists of three layers: the collagen-rich fibrosa (upper layer,
Fig 2A through 2F), the spongiosa (central layer), and the
elastin-rich ventricularis (bottom layer, Fig 2A
through 2F). In this leaflet, there is an association between
osteopontin protein (black immunoreaction product of the
anti-osteopontin antiserum, Fig 2C) and macroscopic
calcification
(black staining with von Kossa's stain, Fig 2D). Only
scattered
macrophages are present in the ventricularis
and in the spongiosa (black reaction product of the anti-CD68
anti-macrophage antibody, Fig 2E), but no
macrophages are present in the area with osteopontin and
calcification. The absence of SMCs or myofibroblasts from the regions
of calcification is demonstrated by the absence of staining in the
fibrosa with an antibody against -actin (Fig 2F). This
association of calcification with osteopontin protein, occurring in the
absence of macrophage accumulation, was uncommon, being
present in leaflets from 2 of 14 patients. Three additional
patients had neither microscopic nor macroscopic calcification nor
immunohistochemically detectable osteopontin protein. Thus, all 11
valve leaflets with calcification contained osteopontin protein,
whereas 9 of the 11 also contained macrophages in regions with
osteopontin protein.
|
Statistical Analysis of Immunohistochemistry
Findings
Mantel-Haenszel's tests for linear association were
performed for
each of the three anatomic regions of the leaflets for the comparisons
of the semiquantitative assessments of osteopontin expression and
calcification and of the semiquantitative assessments of osteopontin
expression and macrophage accumulation, as described in
"Methods." The Table lists the Mantel-Haenszel
test scores at each of the three anatomic regions of the
leaflets, namely, base, midportion, and tip, for the comparison of
osteopontin versus calcification and osteopontin versus
macrophage accumulation. The Mantel-Haenszel scores indicate
highly statistically significant associations between the amount of
osteopontin and the degree of calcification for each of the three
regions of the leaflet. Likewise, the scores also indicate highly
significant associations between the amount of osteopontin and the
amount of macrophage accumulation.
|
In Situ Hybridization
To determine which cell types in the
lesion synthesize
osteopontin, in situ hybridization was performed on formalin-fixed
aortic valve leaflets obtained from the excised native hearts removed
from nine patients at the time of cardiac transplantation. Aortic
valvular tissue from these patients had been fixed in formalin
within 2 hours of organ removal, thus maximizing mRNA preservation for
in situ hybridization studies. Fig 3 demonstrates the
presence of osteopontin mRNA and protein in one of the valve lesions
examined. In situ hybridization with the 35S-labeled
antisense osteopontin riboprobe (Fig 3A) demonstrates
hybridization in
mononuclear cells in a developing valve lesion, whereas no specific
hybridization is seen on an adjacent section with the sense (control)
riboprobe (Fig 3B). Staining of an adjacent section with the
CD68
antibody (Fig 3C) demonstrates that these cells represent a
subset of macrophages, thus confirming that a subset of lesion
macrophages can synthesize osteopontin. The presence of
osteopontin protein in these cells is confirmed with the LF7 antiserum
(Fig 3D). Staining of neighboring sections with the -actin
antibody and a CD3 antiserum6 confirmed the absence of
SMCs and T lymphocytes from this osteopontin mRNA- and
protein-containing region (data not shown). Scattered extracellular
staining for osteopontin is present in the region adjacent to these
osteopontin mRNA-positive macrophages (short black arrows, Fig
3D). Expression of osteopontin mRNA by other cell types in the
valves,
eg, fibroblasts or SMCs, was not detected on these specimens with this
technique. Further, the occasional macrophages typically
present in the ventricularis of nondiseased
valves6 did not contain osteopontin mRNA or protein.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
Nonrheumatic valvular aortic stenosis is a common disease of the elderly, and as such has been termed a degenerative condition,2 3 4 5 even though the majority of elderly individuals do not have clinically significant aortic stenosis.1 In valvular aortic stenosis, there is prominent deposition of calcium, which plays a major role in limiting valve mobility.2 3 4 5 The recent demonstration that the developing lesion of aortic stenosis contains chronic inflammatory cells6 raised the possibility that inflammatory cells modulate calcium deposition in aortic valvular tissue. This study is the first to demonstrate the presence and active synthesis in aortic valvular tissue of a protein, osteopontin, implicated in both normal7 8 13 and dystrophic calcification16 17 20 21 22 23 in a variety of other tissues. Further, the study demonstrates significant associations between the degree of osteopontin present and the degrees of calcification and macrophage accumulation. Finally, in situ hybridization studies demonstrate that a subset of macrophages in aortic valvular tissue may actively synthesize the osteopontin protein.
Several different proteins have been implicated in calcium deposition in bone and other tissues including, but not limited to, bone morphogenetic protein-2a (BMP-2a),28 matrix Gla protein,22 osteonectin,18 and osteopontin.16 17 18 19 20 21 22 23 These proteins have been studied in a disease with chronic inflammation that has several similarities to valvular aortic stenosis, namely, atherosclerosis. Boström et al28 used in situ hybridization to detect BMP-2a mRNA in calcified areas of three human carotid endarterectomy specimens. The cell types expressing BMP-2a were not directly identified on tissue sections, but the authors were able to culture a subset of vascular cells that had several characteristics of vascular pericytes and that could be shown to express BMP-2a mRNA in vitro.28 These authors subsequently showed that these "calcifying vascular cells" also express osteopontin.29 Also, matrix Gla protein, another bone-associated protein, has been detected in human atherosclerotic plaques.22 The observation that BMP-2a, matrix Gla protein, and osteopontin are present both in bone and in calcified vascular tissue suggests that bone and vascular calcification may be very similar processes. In contrast, expression of osteonectin, another protein implicated in calcium deposition, has been shown by Northern blotting and by in situ hybridization to be inversely correlated with atherosclerosis and calcification in human atherosclerotic tissue,18 suggesting that there may be some differences in the regulation of calcification in bone compared with vascular tissue.
Osteopontin has been studied in a variety of normal and pathological circumstances. In bone, osteopontin may be secreted by both osteoblasts and osteoclasts but is invariably present at the forming surface of bone. Further, osteopontin has been posited to play a role in mineral deposition, since it has a high affinity for hydroxyapatite, the major form of calcium and phosphate in bone,7 artery wall,28 and aortic valves.30 The observation that osteopontin is made by osteoclasts has raised the possibility that the protein also plays a role in bone resorption.31 32 Also, osteopontin is synthesized in a variety of tissues in which calcium deposition does not occur33 ; therefore, the protein may have other as yet undetermined roles.
However, osteopontin is unique among the noncollagenous matrix proteins of bone for the frequency with which it has been identified in conditions with pathological or dystrophic calcium deposition, such as nephrolithiasis16 17 and atherosclerosis.19 20 21 22 23 The finding that osteopontin is present in aortic valvular lesions and is associated with calcification suggests that calcium deposition in this tissue is, at least in part, an actively regulated and therefore potentially modifiable process. However, these results do not determine whether the effect of osteopontin is to mediate calcium deposition or removal. For example, whereas some authors have suggested that osteopontin mediates renal stone formation,16 17 another has suggested an inhibitory role for osteopontin in nephrolithiasis.18 Further, the demonstration that osteopontin is actively synthesized in aortic valve lesions raises the possibility that, as in bone, other proteins implicated in the regulation of calcium deposition11 12 29 may be involved in aortic valve mineralization. The possibility that proteins implicated in bone formation may play a role in aortic valve calcification is further supported by the observations that histologically identifiable bone is present in some aortic valves subjected to balloon valvuloplasty34 and that human aortic valve calcification contains spheroidal particles similar to calcium phosphate particles in bone.35 In addition, lipid deposition36 and abnormal calcium homeostasis37 may play important roles in aortic valve calcification.
This study demonstrates that a subset of valve macrophages actively synthesize osteopontin protein in aortic valvular tissue. Other studies similarly have demonstrated that macrophages may synthesize osteopontin mRNA19 22 and contain osteopontin protein22 in human atherosclerotic plaques; therefore, detection of osteopontin in macrophages has precedent. It also has been shown by immunohistochemistry20 22 23 and by in situ hybridization20 21 that osteopontin protein can be detected on vascular SMCs. The present study was not able to demonstrate osteopontin expression by another cell type of mesenchymal origin, ie, valve fibroblasts, which may express actin in areas of aortic valvular lesion formation.6 However, because SMCs are not a typical component of aortic valvular lesions, the lack of osteopontin expression by fibroblasts in the present study is not directly comparable. Finally, because circulating osteopontin levels are low, the present study suggests that macrophages may be the primary source of osteopontin protein in valve tissue. However, it should be emphasized that osteopontin expression does not appear to be a basal or normal function of macrophages in this tissue, as evidenced by the lack of expression of the protein by this cell type either in nondiseased aortic valves or in nonlesioned areas of diseased aortic valves, both of which frequently contain resident macrophages.6 This suggests that, in aortic valves, osteopontin expression by macrophages is inducible rather than constitutive and pathological rather than normal.
It is interesting to consider why, although the lesions of both aortic stenosis and atherosclerosis have inflammatory components, there has been poor correlation between the two diseases in humans.38 The answer may be related, in part, to differences in the circumstances under which the two conditions become clinically apparent. In the case of aortic stenosis, excessive valve rigidity, through a combination of leaflet calcification and fibrosis, results in constriction of the valve orifice and the development of symptoms. In contrast, the acute clinical syndromes of atherosclerosis, such as acute myocardial infarction or unstable angina, typically occur when lipid deposition or macrophage infiltration weakens the plaque and results in plaque rupture.39 40 41 42 Thus, although both aortic stenosis and atherosclerosis may develop as a result of chronic inflammation, the first is clinically manifest when the response to inflammation causes excessive valve rigidity, whereas the second becomes clinically apparent when the inflammatory response weakens the plaque. Thus, individuals may have differences in susceptibility to the two conditions, depending on whether their calcific and/or fibrotic response to inflammatory injury is vigorous or weak.
In summary, osteopontin, a protein implicated in normal and dystrophic calcification in a variety of tissues, is present in the developing and advanced lesions of aortic stenosis. Further, highly statistically significant associations were demonstrated between the amount of osteopontin protein present and both the degree of calcification and the accumulation of macrophages. Finally, in situ hybridization studies confirmed that a subset of lesion macrophages were actively synthesizing osteopontin. These results are consistent with the hypotheses that, rather than representing a degenerative and unmodifiable process, calcification in valvular aortic stenosis is, at least in part, an active process in which inflammatory cells may participate. Further, the results are consistent with the possibility that valvular aortic stenosis is preventable, either by modification of the inflammatory process or by alteration of expression of proteins, such as osteopontin, which may modulate calcium deposition in this tissue.
|
Acknowledgments |
|---|
This work was supported, in part, by a Grant-in-Aid (91-007520) from the American Heart Association to Dr Otto, by a Grant-in-Aid from the American Heart Association, Washington Affiliate, to Dr O'Brien (94-WA-518R), and by grants from the NHLBI to Dr Alpers (HL-42270 and HL-47151). Dr O'Brien is the recipient of a Clinical Investigator Development Award from the NHLBI (HL-02788). The authors thank Lisa Anne Billings for assistance in preparing the manuscript and Winnie Chiu, Susan Rozell, and Kay Gurley for technical assistance.
|
Footnotes |
|---|
Reprint requests to Kevin D. O'Brien, MD, Division of Cardiology, RG-22, Department of Medicine, University of Washington, Seattle, WA 98195. E-mail cardiac@u.washington.edu.
Received December 13, 1994; revision received February 28, 1995; accepted February 28, 1995.
|
References |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
1. Lindroos M, Kupari M, Heikkilä J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol. 1993;21:1220-1225. [Abstract]
2. Rackley CE, Edwards JE, Wallace RB, Katz NM. Aortic valve disease: aortic stenosis: etiology. In: Hurst JW, ed. The Heart. New York, NY: McGraw-Hill Book Co; 1986:729.
3. Braunwald E. Valvular heart disease: aortic stenosis, etiology and pathology. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, Pa: WB Saunders Co; 1992:1035-1036.
4. Edwards WD. Surgical pathology of the aortic valve: degenerative disease. In: Waller BF, ed. Pathology of the Heart and Great Vessels. New York, NY: Churchill Livingstone; 1988:71-74.
5. Roberts WC. The senile cardiac calcification syndrome. Am J Cardiol. 1986;58:572-574. Editorial. [Medline] [Order article via Infotrieve]
6.
Otto CM, Kuusisto J, Reichenbach DD, Gown AM,
O'Brien, KD. Characterization of the early lesion of
`degenerative' valvular aortic stenosis: histologic
and immunohistochemical studies.
Circulation. 1994;90:844-853.
7.
Oldberg A, Franzen A, Heinegard D. Cloning and
sequence analysis of rat bone sialoprotein (osteopontin) cDNA
reveals an Arg-Gly-Asp cell binding sequence. Proc Natl
Acad Sci U S A. 1986;83:8819-8823.
8. Young MF, Kerr JM, Termine JD, Wewer UM, Wang MG, McBride OW, Fisher LW. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin. Genomics. 1990;7:491-502. [Medline] [Order article via Infotrieve]
9.
Nomura S, Wills AJ, Edwards DR, Heath JK, Hogan
BLH. Developmental expression of 2ar (osteopontin) and SPARC
(osteonectin) RNA as revealed by in situ
hybridization. J Cell Biol. 1988;106:441-450.
10. Boskey AL, Maresca M, Ullrich W, Doty SB, Butler WT, Prince CW. Osteopontin-hydroxyapatite interaction in vitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone Miner. 1993;22:147-159. [Medline] [Order article via Infotrieve]
11. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR. Osteonectin, a bone-specific protein linking mineral to collagen. Cell. 1981;26:99-105. [Medline] [Order article via Infotrieve]
12. Young MF, Day AA, Dominquez P, McQuillan C, Fisher LW, Termine JD. Structure and expression of osteonectin mRNA in human tissue. Connect Tissue Res. 1990;24:17-28. [Medline] [Order article via Infotrieve]
13. Carlson CS, Tulli HM, Jayo MJ, Loeser RF, Tracy RP, Mann KG, Adams MR. Immunolocalization of noncollagenous bone matrix proteins in lumbar vertebrae from intact and surgically menopausal cynomolgus monkeys. J Bone Miner Res. 1993;8:71-81. [Medline] [Order article via Infotrieve]
14.
Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM.
Osteopontin promotes vascular cell adhesion and spreading and is
chemotactic for smooth muscle cells in vitro.
Circ Res. 1994;74:214-224.
15.
Gadeau AP, Campan M, Millet D, Candresse T, Desgranges
C. Osteopontin overexpression is associated with
arterial smooth muscle cell proliferation in vitro.
Arterioscler Thromb. 1993;13:120-125.
16. Kohri K, Suzuki Y, Yoshida K, Yamamoto K, Amasaki N, Yamate T, Umekawa T, Iguchi M, Shinohara H, Kurita T. Molecular cloning and sequencing of cDNA encoding urinary stone protein, which is identical to osteopontin. Biochem Biophys Res Commun. 1992;184:859-864. [Medline] [Order article via Infotrieve]
17.
Kohri K, Nomura S, Kitamura Y, Nagata T, Yoshioka K,
Iguchi M, Yamate T, Umekawa T, Suzuki Y, Shinohara H, Kurita T.
Structure and expression of the mRNA encoding urinary stone
protein (osteopontin). J Biol Chem. 1993;268:15180-15184.
18. Worchester EM, Blumenthal SS, Beshensky AN, Lewand DL. The calcium oxidate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin. J Bone Miner Res. 1992;7:1029-1036. [Medline] [Order article via Infotrieve]
19. Hirota S, Imakita M, Kohri K, Ito A, Morii E, Adachi S, Kim H-M, Kitamura Y, Yutani C, Nomura S. Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques: a possible association with calcification. Am J Pathol. 1993;143:1003-1008. [Abstract]
20. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest. 1993;92:1686-1696.
21. Ikeda T, Shirasawa T, Esaki Y, Yoshiki S, Hirokawa K. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest. 1993;92:2814-2820.
22. Shanahan CM, Cary NRB, Metcalfe JC, Weissberg PL. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest. 1994;93:2393-2402.
23. Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse calcification in human coronary arteries: association of osteopontin with atherosclerosis. J Clin Invest. 1994;94:1597-1604.
24. Bacchi CE, Marsh CL, Perkins CD, Carithers RL, McVicar JP, Hudkins KL, Benjamin CD, Martin JM, Lobb R, Alpers CE. Expression of vascular cell adhesion molecule (VCAM-1) in liver and pancreas allograft rejection. Am J Pathol. 1993;142:579-591. [Abstract]
25.
Skalli O, Ropraz P, Trzeciak A, Benzonan G, Gillessen
D, Gabbiani G. A monoclonal antibody against -smooth
muscle actin: a new probe for smooth muscle differentiation.
J Cell Biol. 1986;103:2787-2796.
26. O'Brien KD, Gordon D, Deeb SS, Ferguson M, Chait A. Lipoprotein lipase is synthesized by macrophage-derived foam cells in human coronary atherosclerotic plaques. J Clin Invest. 1992;89:1544-1550.
27. O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, McCarty J, Ferguson M, Hudkins K, Benjamin CD, Lobb R, Alpers CE. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques: implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest. 1993;92:945-951.
28. Boström K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993;91:1800-1809.
29. Watson KE, Boström K, Ravindranath R, Lam T, Norton B, Demer LL. TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-line vascular cells to calcify. J Clin Invest. 1994;93:2106-2113.
30. Anderson HC. Calcific diseases: a concept. Arch Pathol Lab Med. 1983;107:341-348. [Medline] [Order article via Infotrieve]
31.
Reinholt FP, Hultenby K, Oldberg A, Heingard D.
Osteopontin: a possible anchor of osteoclasts to bone.
Proc Natl Acad Sci U S A. 1990;87:4473-4475.
32. Arai M, Ohya K, Ogura H. Osteopontin mRNA expression during bone resorption: an in situ hybridization study of induced ectopic bone in the rat. Bone Miner. 1993;22:129-145. [Medline] [Order article via Infotrieve]
33. Brown LF, Berse B, Van De Water L, Papadopoulos-Sergiou A, Perruzzi CA, Manseau EJ, Dvorak HF, Senger DR. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell. 1992;3:1169-1180. [Abstract]
34. Feldman T, Glagov S, Carroll JD. Restenosis following successful balloon valvuloplasty: bone formation in aortic valve leaflets. Cathet Cardiovasc Diagn. 1993;29:1-7. [Medline] [Order article via Infotrieve]
35. Kim KM, Trump BF. Amorphous calcium precipitations in human aortic valve. Calcif Tissue Res. 1975;18:155-160. [Medline] [Order article via Infotrieve]
36. Rossi MH, Braile DM, Teixera MD, Sousa DR, Peres LC. Lipid extraction attenuates the calcific degeneration of bovine pericardium used in cardiac valve bioprostheses. J Exp Pathol (Oxford). 1990;71:187-196. [Medline] [Order article via Infotrieve]
37. Roberts WC, Waller BF. Effect of chronic hypercalcemia on the heart: an analysis of 18 necropsy patients. Am J Med. 1981;71:371-384. [Medline] [Order article via Infotrieve]
38. Georgeson S, Meyer KB, Pauker SG. Decision analysis in clinical cardiology: when is coronary angiography required in aortic stenosis? J Am Coll Cardiol. 1990;15:751-762. [Abstract]
39.
van der Wal AC, Becker AE, van der Loos CM, Das PK.
Site of intimal rupture or erosion of thrombosed
coronary atherosclerotic plaques is characterized by an
inflammatory process irrespective of the dominant plaque
morphology. Circulation. 1994;89:36-44.
40. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring on coronary atherosclerotic plaques. Lancet. 1989;88:995-1004.
41. Lendon CL, Davies MJ, Born GVR, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophages density increases. Atherosclerosis. 1991;87:87-90. [Medline] [Order article via Infotrieve]
42.
Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J.
Risks of thrombosis in human atherosclerotic plaques: role of
extracellular lipid, macrophage, and smooth muscle cell
content. Br Heart J. 1993;69:377-381.
This article has been cited by other articles:
 |
|
 |
|
  T. V. Tkatchenko, R. A. Moreno-Rodriguez, S. J. Conway, J. D. Molkentin, R. R. Markwald, and A. V. Tkatchenko Lack of periostin leads to suppression of Notch1 signaling and calcific aortic valve disease Physiol Genomics, November 1, 2009; 39(3): 160 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-J. Yu, A. Skolnick, G. Ferrari, K. Heretis, P. Mignatti, G. Pintucci, B. Rosenzweig, J. Diaz-Cartelle, I. Kronzon, G. Perk, et al. Correlation between plasma osteopontin levels and aortic valve calcification: Potential insights into the pathogenesis of aortic valve calcification and stenosis J. Thorac. Cardiovasc. Surg., July 1, 2009; 138(1): 196 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Barrick, R. B. Roberts, M. Rojas, N. M. Rajamannan, C. B. Suitt, K. D. O'Brien, S. S. Smyth, and D. W. Threadgill Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H65 - H75. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Akat, M Borggrefe, and J J Kaden Aortic valve calcification: basic science to clinical practice Heart, April 1, 2009; 95(8): 616 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Rajamannan Calcific Aortic Stenosis: Lessons Learned From Experimental and Clinical Studies Arterioscler Thromb Vasc Biol, February 1, 2009; 29(2): 162 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Kanazawa, T. Yamaguchi, M. Yamamoto, M. Yamauchi, S. Kurioka, S. Yano, and T. Sugimoto Serum Osteocalcin Level Is Associated with Glucose Metabolism and Atherosclerosis Parameters in Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 45 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Rossebo, T. R. Pedersen, K. Boman, P. Brudi, J. B. Chambers, K. Egstrup, E. Gerdts, C. Gohlke-Barwolf, I. Holme, Y. A. Kesaniemi, et al. Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis N. Engl. J. Med., September 25, 2008; 359(13): 1343 - 1356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Bosse, P. Mathieu, and P. Pibarot Genomics: The Next Step to Elucidate the Etiology of Calcific Aortic Valve Stenosis J. Am. Coll. Cardiol., April 8, 2008; 51(14): 1327 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Towler Vascular Calcification: A Perspective On An Imminent Disease Epidemic IBMS BoneKEy, February 1, 2008; 5(2): 41 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. O. McDonald, R. G. Gerrity, C. Jen, H.-J. Chen, K. Wark, T. N. Wight, A. Chait, and K. D. O'Brien Diabetes and Arterial Extracellular Matrix Changes in a Porcine Model of Atherosclerosis J. Histochem. Cytochem., November 1, 2007; 55(11): 1149 - 1157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Scatena, L. Liaw, and C. M. Giachelli Osteopontin: A Multifunctional Molecule Regulating Chronic Inflammation and Vascular Disease Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2302 - 2309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Liu, V. R. Joag, and A. I. Gotlieb The Emerging Role of Valve Interstitial Cell Phenotypes in Regulating Heart Valve Pathobiology Am. J. Pathol., November 1, 2007; 171(5): 1407 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.J. Grande-Allen, N. Osman, M.L. Ballinger, H. Dadlani, S. Marasco, and P.J. Little Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease Cardiovasc Res, October 1, 2007; 76(1): 19 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H Chester and P. M Taylor Molecular and functional characteristics of heart-valve interstitial cells Phil Trans R Soc B, August 29, 2007; 362(1484): 1437 - 1443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. S. Ertas, T. Hasan, C. Ozdol, S. Gulec, Y. Atmaca, C. Tulunay, H. Karabulut, H. T. Kocum, I. Dincer, K. S. Kose, et al. Relationship Between Angiotensin-Converting Enzyme Gene Polymorphism and Severity of Aortic Valve Calcification Mayo Clin. Proc., August 1, 2007; 82(8): 944 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Kiel, J. Magaziner, S. Zimmerman, L. Ball, B. A. Barton, K. M. Brown, J. P. Stone, D. Dewkett, and S. J. Birge Efficacy of a Hip Protector to Prevent Hip Fracture in Nursing Home Residents: The HIP PRO Randomized Controlled Trial JAMA, July 25, 2007; 298(4): 413 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Clark-Greuel, J. M. Connolly, E. Sorichillo, N. R. Narula, H. S. Rapoport, E. R. Mohler III, J. H. Gorman III, R. C. Gorman, and R. J. Levy Transforming Growth Factor-{beta}1 Mechanisms in Aortic Valve Calcification: Increased Alkaline Phosphatase and Related Events Ann. Thorac. Surg., March 1, 2007; 83(3): 946 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. O'Brien Pathogenesis of Calcific Aortic Valve Disease: A Disease Process Comes of Age (and a Good Deal More) Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1721 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Helske, S. Syvaranta, K. A. Lindstedt, J. Lappalainen, K. Oorni, M. I. Mayranpaa, J. Lommi, H. Turto, K. Werkkala, M. Kupari, et al. Increased Expression of Elastolytic Cathepsins S, K, and V and Their Inhibitor Cystatin C in Stenotic Aortic Valves Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1791 - 1798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. Caira, S. R. Stock, T. G. Gleason, E. C. McGee, J. Huang, R. O. Bonow, T. C. Spelsberg, P. M. McCarthy, S. H. Rahimtoola, and N. M. Rajamannan Human Degenerative Valve Disease Is Associated With Up-Regulation of Low-Density Lipoprotein Receptor-Related Protein 5 Receptor-Mediated Bone Formation J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1707 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Liebe, M. Brueckmann, M. Borggrefe, and J. J. Kaden Statin therapy of calcific aortic stenosis: hype or hope? Eur. Heart J., April 1, 2006; 27(7): 773 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Visconti, Y. Ebihara, A. C. LaRue, P. A. Fleming, T. C. McQuinn, M. Masuya, H. Minamiguchi, R. R. Markwald, M. Ogawa, and C. J. Drake An In Vivo Analysis of Hematopoietic Stem Cell Potential: Hematopoietic Origin of Cardiac Valve Interstitial Cells Circ. Res., March 17, 2006; 98(5): 690 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Drolet, E. Roussel, Y. Deshaies, J. Couet, and M. Arsenault A High Fat/High Carbohydrate Diet Induces Aortic Valve Disease in C57BL/6J Mice J. Am. Coll. Cardiol., February 21, 2006; 47(4): 850 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Rajamannan, M. Subramaniam, F. Caira, S. R. Stock, and T. C. Spelsberg Atorvastatin Inhibits Hypercholesterolemia-Induced Calcification in the Aortic Valves via the Lrp5 Receptor Pathway Circulation, August 30, 2005; 112(9_suppl): I-229 - I-234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. V. Freeman and C. M. Otto Spectrum of Calcific Aortic Valve Disease: Pathogenesis, Disease Progression, and Treatment Strategies Circulation, June 21, 2005; 111(24): 3316 - 3326. [Full Text] [PDF]
|
|
|
|
|
|
N. M. Rajamannan, T. B. Nealis, M. Subramaniam, S. Pandya, S. R. Stock, C. I. Ignatiev, T. J. Sebo, T. K. Rosengart, W. D. Edwards, P. M. McCarthy, et al. Calcified Rheumatic Valve Neoangiogenesis Is Associated With Vascular Endothelial Growth Factor Expression and Osteoblast-Like Bone Formation Circulation, June 21, 2005; 111(24): 3296 - 3301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.D.M. Collett and A.E. Canfield Angiogenesis and Pericytes in the Initiation of Ectopic Calcification Circ. Res., May 13, 2005; 96(9): 930 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Kuusisto, K Rasanen, T Sarkioja, E Alarakkola, and V-M Kosma Atherosclerosis-like lesions of the aortic valve are common in adults of all ages: a necropsy study Heart, May 1, 2005; 91(5): 576 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Y. Speer, Y.-C. Chien, M. Quan, H.-Y. Yang, H. Vali, M. D. McKee, and C. M. Giachelli Smooth muscle cells deficient in osteopontin have enhanced susceptibility to calcification in vitro Cardiovasc Res, May 1, 2005; 66(2): 324 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. O'Brien, J. L. Probstfield, M. T. Caulfield, K. Nasir, J. Takasu, D. M. Shavelle, A. H. Wu, X.-Q. Zhao, and M. J. Budoff Angiotensin-Converting Enzyme Inhibitors and Change in Aortic Valve Calcium Arch Intern Med, April 25, 2005; 165(8): 858 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Giachelli, M. Y. Speer, X. Li, R. M. Rajachar, and H. Yang Regulation of Vascular Calcification: Roles of Phosphate and Osteopontin Circ. Res., April 15, 2005; 96(7): 717 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Simmons, G. R. Grant, E. Manduchi, and P. F. Davies Spatial Heterogeneity of Endothelial Phenotypes Correlates With Side-Specific Vulnerability to Calcification in Normal Porcine Aortic Valves Circ. Res., April 15, 2005; 96(7): 792 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Seipelt, C. L. Backer, C. Mavroudis, V. Stellmach, M. Cornwell, I. M. Seipelt, F. A. Schoendube, and S. E. Crawford Osteopontin expression and adventitial angiogenesis induced by local vascular endothelial growth factor 165 reduces experimental aortic calcification J. Thorac. Cardiovasc. Surg., April 1, 2005; 129(4): 773 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Helske, K. A. Lindstedt, M. Laine, M. Mayranpaa, K. Werkkala, J. Lommi, H. Turto, M. Kupari, and P. T. Kovanen Induction of local angiotensin II-producing systems in stenotic aortic valves J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1859 - 1866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Messika-Zeitoun, M.-C. Aubry, D. Detaint, L. F. Bielak, P. A. Peyser, P. F. Sheedy, S. T. Turner, J. F. Breen, C. Scott, A. J. Tajik, et al. Evaluation and Clinical Implications of Aortic Valve Calcification Measured by Electron-Beam Computed Tomography Circulation, July 20, 2004; 110(3): 356 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mazzone, M. C. Epistolato, R. De Caterina, S. Storti, S. Vittorini, S. Sbrana, J. Gianetti, S. Bevilacqua, M. Glauber, A. Biagini, et al. Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis J. Am. Coll. Cardiol., May 5, 2004; 43(9): 1670 - 1676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Piper, R. Bergemann, H. D. Schulte, R. Koerfer, and D. Horstkotte Can progression of valvar aortic stenosis be predicted accurately? Ann. Thorac. Surg., September 1, 2003; 76(3): 676 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-L. Chan Is aortic stenosis a preventable disease? J. Am. Coll. Cardiol., August 20, 2003; 42(4): 593 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M Rajamannan, B. Gersh, and R. O Bonow CALCIFIC AORTIC STENOSIS: FROM BENCH TO THE BEDSIDE--EMERGING CLINICAL AND CELLULAR CONCEPTS Heart, July 1, 2003; 89(7): 801 - 805. [Full Text] [PDF]
|
|
|
|
|
|
N. M. Rajamannan, M. Subramaniam, D. Rickard, S. R. Stock, J. Donovan, M. Springett, T. Orszulak, D. A. Fullerton, A.J. Tajik, R. O. Bonow, et al. Human Aortic Valve Calcification Is Associated With an Osteoblast Phenotype Circulation, May 6, 2003; 107(17): 2181 - 2184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Thistlethwaite Invited commentary Ann. Thorac. Surg., February 1, 2003; 75(2): 465 - 466. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Wesson, R. J. Johnson, M. Mazzali, A. M. Beshensky, S. Stietz, C. Giachelli, L. Liaw, C. E. Alpers, W. G. Couser, J. G. Kleinman, et al. Osteopontin Is a Critical Inhibitor of Calcium Oxalate Crystal Formation and Retention in Renal Tubules J. Am. Soc. Nephrol., January 1, 2003; 14(1): 139 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Bellamy, P. A. Pellikka, K. W. Klarich, A. J. Tajik, and M. Enriquez-Sarano Association of cholesterol levels, hydroxymethylglutaryl coenzyme-a reductase inhibitor treatment, and progression of aortic stenosis in the community J. Am. Coll. Cardiol., November 20, 2002; 40(10): 1723 - 1730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Pearlman Medical treatment ofaortic stenosis: Promising, or wishful thinking? J. Am. Coll. Cardiol., November 20, 2002; 40(10): 1731 - 1734. [Full Text] [PDF]
|
|
|
|
|
|
K. D. O'Brien, D. M. Shavelle, M. T. Caulfield, T. O. McDonald, K. Olin-Lewis, C. M. Otto, and J. L. Probstfield Association of Angiotensin-Converting Enzyme With Low-Density Lipoprotein in Aortic Valvular Lesions and in Human Plasma Circulation, October 22, 2002; 106(17): 2224 - 2230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Y. Speer, M. D. McKee, R. E. Guldberg, L. Liaw, H.-Y. Yang, E. Tung, G. Karsenty, and C. M. Giachelli Inactivation of the Osteopontin Gene Enhances Vascular Calcification of Matrix Gla Protein-deficient Mice: Evidence for Osteopontin as an Inducible Inhibitor of Vascular Calcification In Vivo J. Exp. Med., October 21, 2002; 196(8): 1047 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C M Otto Calcification of bicuspid aortic valves Heart, October 1, 2002; 88(4): 321 - 322. [Full Text] [PDF]
|
|
|
|
|
|
A. I. Gotlieb, A. Rosenthal, and P. Kazemian Fibroblast growth factor 2 regulation of mitral valve interstitial cell repair in vitro J. Thorac. Cardiovasc. Surg., September 1, 2002; 124(3): 591 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Mohler III Vascular calcification: good, bad or ugly? Vascular Medicine, August 1, 2002; 7(3): 161 - 162. [PDF]
|
|
|
|
 |
|
 L. L Demer Vascular calcification and osteoporosis: inflammatory responses to oxidized lipids Int. J. Epidemiol., August 1, 2002; 31(4): 737 - 741. [Full Text] [PDF]
|
|
|
|
|
|
F. Robicsek, M. J. Thubrikar, and A. A. Fokin Cause of degenerative disease of the trileaflet aortic valve: review of subject and presentation of a new theory Ann. Thorac. Surg., April 1, 2002; 73(4): 1346 - 1354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tintut, J. Patel, M. Territo, T. Saini, F. Parhami, and L. L. Demer Monocyte/Macrophage Regulation of Vascular Calcification In Vitro Circulation, February 5, 2002; 105(5): 650 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Satta, J. Melkko, R. Pollanen, J. Tuukkanen, P. Paakko, P. Ohtonen, A. Mennander, and Y. Soini Progression of human aortic valve stenosis is associated with tenascin-C expression J. Am. Coll. Cardiol., January 2, 2002; 39(1): 96 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mazzali, T. Kipari, V. Ophascharoensuk, J.A. Wesson, R. Johnson, and J. Hughes Osteopontin--a molecule for all seasons QJM, January 1, 2002; 95(1): 3 - 13. [Full Text] [PDF]
|
|
|
|
|
|
L. L. Demer Cholesterol in Vascular and Valvular Calcification Circulation, October 16, 2001; 104(16): 1881 - 1883. [Full Text] [PDF]
|
|
|
|
|
|
A. Y. M. WANG, J. WOO, M. WANG, M. M. M. SEA, R. IP, P. K. T. LI, S. F. LUI, and J. E. SANDERSON Association of Inflammation and Malnutrition with Cardiac Valve Calcification in Continuous Ambulatory Peritoneal Dialysis Patients J. Am. Soc. Nephrol., September 1, 2001; 12(9): 1927 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Jian, P. L. Jones, Q. Li, E. R. Mohler III, F. J. Schoen, and R. J. Levy Matrix Metalloproteinase-2 Is Associated with Tenascin-C in Calcific Aortic Stenosis Am. J. Pathol., July 1, 2001; 159(1): 321 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M OTTO and K. D O'BRIEN Why is there discordance between calcific aortic stenosis and coronary artery disease? Heart, June 1, 2001; 85(6): 601 - 602. [Full Text]
|
|
|
|
|
|
E. R. Mohler III, F. Gannon, C. Reynolds, R. Zimmerman, M. G. Keane, and F. S. Kaplan Bone Formation and Inflammation in Cardiac Valves Circulation, March 20, 2001; 103(11): 1522 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Otto Aortic Stenosis -- Listen to the Patient, Look at the Valve N. Engl. J. Med., August 31, 2000; 343(9): 652 - 654. [Full Text]
|
|
|
|
|
|
H. Min, S. Morony, I. Sarosi, C. R. Dunstan, C. Capparelli, S. Scully, G. Van, S. Kaufman, P. J. Kostenuik, D. L. Lacey, et al. Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis J. Exp. Med., August 21, 2000; 192(4): 463 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Kennedy, D. Henrion, M. Wassef, C. M. Shanahan, G. Bloch, and A. Tedgui Osteopontin expression and calcium content in human aortic valves J. Thorac. Cardiovasc. Surg., August 1, 2000; 120(2): 427 - 427. [Full Text]
|
|
|
|
|
|
C. M. Otto, B. K. Lind, D. W. Kitzman, B. J. Gersh, D. S. Siscovick, and The Cardiovascular Health Study Association of Aortic-Valve Sclerosis with Cardiovascular Mortality and Morbidity in the Elderly N. Engl. J. Med., July 15, 1999; 341(3): 142 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Giachelli Ectopic Calcification : Gathering Hard Facts about Soft Tissue Mineralization Am. J. Pathol., March 1, 1999; 154(3): 671 - 675. [Full Text] [PDF]
|
|
|
|
|
|
K. M. Kim, G. A. Herrera, and H. D. Battarbee Role of Glutaraldehyde in Calcification of Porcine Aortic Valve Fibroblasts Am. J. Pathol., March 1, 1999; 154(3): 843 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wada, M. D. McKee, S. Steitz, and C. M. Giachelli Calcification of Vascular Smooth Muscle Cell Cultures : Inhibition by Osteopontin Circ. Res., February 5, 1999; 84(2): 166 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Demer and Y. Tintut Osteopontin : Between a Rock and a Hard Plaque Circ. Res., February 5, 1999; 84(2): 250 - 252. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Bucay, I. Sarosi, C. R. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S. Scully, H. L. Tan, W. Xu, D. L. Lacey, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes & Dev., May 1, 1998; 12(9): 1260 - 1268. [Abstract] [Full Text]
|
|
|
|
|
|
C. M. Otto, I. G. Burwash, M. E. Legget, B. I. Munt, M. Fujioka, N. L. Healy, C. D. Kraft, C. Y. Miyake-Hull, and R. G. Schwaegler Prospective Study of Asymptomatic Valvular Aortic Stenosis : Clinical, Echocardiographic, and Exercise Predictors of Outcome Circulation, May 6, 1997; 95(9): 2262 - 2270. [Abstract] [Full Text]
|
|
|
|
|
|
E. R. Mohler III, L. P. Adam, P. McClelland, L. Graham, and D. R. Hathaway Detection of Osteopontin in Calcified Human Aortic Valves Arterioscler Thromb Vasc Biol, March 1, 1997; 17(3): 547 - 552. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. L. Smith, H.-K. Cheung, L. E. Ling, J. Chen, D. Sheppard, R. Pytela, and C. M. Giachelli Osteopontin N-terminal Domain Contains a Cryptic Adhesive Sequence Recognized by alpha 9beta 1 Integrin J. Biol. Chem., November 8, 1996; 271(45): 28485 - 28491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. O'Brien, D. D. Reichenbach, S. M. Marcovina, J. Kuusisto, C. E. Alpers, and C. M. Otto Apolipoproteins B, (a), and E Accumulate in the Morphologically Early Lesion of `Degenerative' Valvular Aortic Stenosis Arterioscler Thromb Vasc Biol, April 1, 1996; 16(4): 523 - 532. [Abstract] [Full Text]
|
|
|
|
|
|
L. L. Demer A Skeleton in the Atherosclerosis Closet Circulation, October 15, 1995; 92(8): 2029 - 2032. [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||